FIRST ADDENDUM TO LICENSE AND SERVICE AGREEMENTLicense and Service Agreement • May 9th, 2023 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST ADDENDUM ("First ·Addendum"), is made and entered into, effective as of April 21, 2009 ("First Addendum Date"), by and between Revance Therapeutics, Inc., having a principal place of business at 2400 Bayshore Parkway, Suite 100, Mountain View, CA 94043 ("Revance") and List Biological Laboratories, Inc., having a principal place of business at 540 Division Street, Campbell, CA 95008 ("List"), (collectively, the "Parties" or individually, a "Party").
THIRD AMENDMENT TO LEASELease • May 9th, 2023 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (the “Amendment”) is made effective as of the last date of execution on the signature page hereto (the “Effective Date”), by and between 1222 DEMONBREUN, LP, a Texas limited partnership (“Landlord”), and REVANCE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
March 22, 2023 By Email & Federal Express Ning Yuan Re: Second Letter Amendment to the License Agreement Dear Ning,License Agreement • May 9th, 2023 • Revance Therapeutics, Inc. • Pharmaceutical preparations
As you are aware, Revance Therapeutics, Inc. ("Revance") and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun") are Parties to a License Agreement ("License Agreement") effective December 4, 2018, as amended by the Letter Amendment to the License Agreement effective December 4 2018 ("First Amendment") effective February 15, 2020. This second letter amendment to the License Agreement ("Second Amendment") sets forth and confirms the understanding between the Parties with respect to certain obligations under the License Agreement. Unless otherwise defined within this Second Amendment, a capitalized term within this Second Amendment shall have the same meaning given to the same capitalized term within the License Agreement.
LICENSE AND SERVICE AGREEMENTLicense and Service Agreement • May 9th, 2023 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This License and Service Agreement (together with any Attachments hereto, the "Agreement") is entered into as of February 8, 2007 (the "Effective Date"), by and between Revance Therapeutics, Inc., ("Revance"), a Delaware corporation, with its principal offices at 2400 Bayshore Parkway, Suite 100, Mountain View, CA 94043 and List Biological Laboratories, Inc., ("List"), a California corporation with its principal offices at 540 Division Street, Campbell, CA 95008. Revance and List are sometimes referred to herein individually as a "Party" and collectively as the "Parties", and references to "Revance" and "List" shall include their respective Affiliates.
